nepafenac (Nevenac)

following an abbreviated submission:

nepafenac (Nevanac®) 3mg/mL eye drops are accepted for use within NHS Scotland.

Indication under review: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Nepafenac 3mg/mL eye drops provide a once daily alternative to nepafenac 1mg/mL eye drops (administered three times daily).  The cost of a course of treatment is the same for both formulations.

Nepafenac 3mg/mL is also licensed for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery. The company submission related only to reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. SMC cannot recommend the use of nepafenac eye drops for postoperative pain and inflammation associated with cataract surgery.